Using semaglutide for losing weight: what the evidence actually says

What semaglutide actually does when you are trying to lose weight

The decision many people reach after months of trying to lose weight is whether medication might genuinely help where diet and exercise alone have not. If you want to understand the science behind it, our page on semaglutide explains how it works in detail, including why it addresses a biological reason those efforts can feel so hard: your body actively defends its weight. GLP-1 is a hormone your gut releases after eating; semaglutide mimics it, binding to receptors in the brain that govern hunger and satiety. The result is a reduced drive to eat, not willpower borrowed from somewhere, but appetite genuinely quietened.

Gastric emptying slows too, so food stays in the stomach longer and fullness comes more readily. That combination is what drove the results in the STEP 1 trial: participants using semaglutide 2.4mg lost roughly 15% of body weight on average over 68 weeks, compared with about 2.4% on placebo. For many people that translates to tens of kilograms. The NHS medicines page for semaglutide explains the mechanism clearly and is worth reading alongside any prescriber conversation.

Importantly, semaglutide is not a standalone fix. The licensed indication pairs it with a reduced-calorie diet and increased activity. What it does is make those changes more sustainable by reducing the constant pull of hunger that derails most long-term attempts.

How the dose schedule shapes your experience of losing weight on semaglutide

One of the most common sources of confusion is the titration schedule. Treatment does not begin at the full maintenance dose. The first weeks are spent at 0.25mg, a level chosen primarily to let your body adjust rather than to produce weight loss. Many people feel frustrated when the scales barely move in month one. That frustration is normal, and it passes.

From there, a prescriber guides you through increases roughly every four weeks: 0.25mg to 0.5mg, then 1.0mg, 1.7mg, and finally 2.4mg. The MHRA approved a higher 7.2mg dose in early 2026; availability at each level is confirmed during your clinical review rather than assumed. Our page on semaglutide weight loss covers what to expect at each stage, including how side effects tend to peak at each dose step and ease within a couple of weeks. Nausea is the most common; constipation, loose stools and indigestion also feature.

If you want a clearer picture of the timeline (specifically when weight loss tends to become noticeable) our page on when you will start losing weight on semaglutide covers that in detail. For most people, meaningful movement on the scales comes once they reach or approach the maintenance dose, not in the first few weeks.

Who semaglutide is licensed to treat in the UK

Wegovy is licensed for adults with a BMI of 30 or above, or 27 or above if at least one weight-related condition is present, for example, high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower thresholds can apply for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, where a 2.5 kg/m² reduction to the standard cutoff reflects differences in health risk at a given BMI.

Those numbers describe the licensed population; they do not guarantee that semaglutide is right for every person who meets them. A prescriber weighs your full history: current medicines, any past history of pancreatitis or thyroid conditions, whether you are pregnant or planning to conceive (semaglutide is not recommended in either case), and whether you are under 18 (it is not licensed below that age). Breastfeeding is another reason treatment would not be appropriate.

The NICE appraisal of semaglutide for weight management (TA875) sets additional criteria for NHS access, including a maximum treatment duration of two years and delivery within a specialist weight management service. Private treatment through a regulated pharmacy operates under the medicine's licence rather than NHS commissioning rules, which is why eligibility can differ between the two routes. Our weight-loss treatments page sets out what that assessment involves at nume.

What to think about before starting, and what happens if you stop

The decision to start semaglutide is not just about whether you qualify. It is also worth thinking through what happens during treatment and after. If you want a realistic sense of what the journey looks like day to day, our page on losing weight on Wegovy covers both the experience during treatment and what the data shows about weight returning when the medicine is stopped, not because the treatment failed, but because the biological appetite suppression that drove the loss is no longer present. Our page on losing weight after Wegovy looks honestly at what that transition involves.

Some people plateau during treatment, which is also worth understanding before you start. A stall after several months does not necessarily mean the medicine has stopped working; it can reflect the body reaching a new set point or changes in activity and diet. There is more on that on the page covering whether you can stop losing weight on Wegovy.

For a broader comparison of semaglutide with other licensed options, our weight-loss overview sets the landscape. And if you want to read about one person's clinical perspective on how these medicines are used in practice, the profile of our clinical lead gives some context. When you feel ready to talk through your own situation, a free consultation with a GPhC-registered prescriber is the right next step, one who reviews your case personally, the same working day. Start your free consultation at our treatment page.